Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Electrothermal bipolar coagulation for pelvic exenterations.

Brian M Slomovitz1, Pedro T Ramirez, Michael Frumovitz

  • 1Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, 1155 Pressler Boulevard, Unit 1362, Houston, TX 77030, USA.

Gynecologic Oncology
|February 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.

Nature communications·2026
Same author

Corrigendum to 'Endometriosis and ovarian cancer risk' [Gynecologic Oncology 209C (2026) 88-98].

Gynecologic oncology·2026
Same author

Study outcome and journal impact factor: a meta-epidemiologic analysis of phase III gynecologic oncology trials.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Endometriosis and ovarian cancer risk.

Gynecologic oncology·2026
Same author

An evaluation of avutometinib in combination with defactinib for <i>KRAS</i>-mutated recurrent low-grade serous ovarian cancer.

Expert review of anticancer therapy·2026

This study found that using an electrothermal bipolar coagulator during pelvic exenteration is safe. The device may reduce intraoperative blood loss and the need for blood transfusions in patients with no other curative options.

Area of Science:

  • Surgical Oncology
  • Minimally Invasive Surgery

Background:

  • Pelvic exenteration is a radical surgical procedure for advanced pelvic malignancies.
  • High morbidity and significant blood loss are common complications.
  • Limited curative options exist for patients requiring this extensive surgery.

Purpose of the Study:

  • To evaluate the safety and efficacy of an electrothermal bipolar coagulator (LigaSure Atlas) in reducing intraoperative blood loss during pelvic exenteration.
  • To assess the impact on transfusion requirements and hospital stay.

Main Methods:

  • A prospective study involving 12 patients undergoing pelvic exenteration (total, anterior, or posterior) between September 2003 and January 2005.
  • The electrothermal bipolar coagulator was used throughout the procedures.

Related Experiment Videos

  • Key outcomes measured included estimated blood loss, transfusion needs, operative time, and length of hospital stay.

    • Main Results:

    • The mean estimated blood loss was 1931 ml, with a mean of 3.4 units of packed red blood cells transfused.
    • The average operative time was 609 minutes, and the mean hospital stay was 19.9 days.
    • No intraoperative complications related to the device were observed, and no reoperations were necessary.

    Conclusions:

    • The electrothermal bipolar coagulator is a safe device for use in pelvic exenteration.
    • Its application may lead to decreased intraoperative blood loss and reduced transfusion requirements.